Ranbaxy Plant Bans To Plague Daiichi Sankyo Long-Term
This article was originally published in PharmAsia News
Daiichi Sankyo faces a long-term drain on production capacity for its generic drugs intended for the U.S. market despite a planned shift of manufacturing to the company’s costlier New Jersey plant.
You may also be interested in...
Recent updates to FDA recalls database also include single lots of three package sizes of Johnson’s Baby Powder after testing found sub-trace levels of chrysotile asbestos contamination and 5,720 bottles of homeopathic OTCs made in India for West Virginia firm Washington Homeopathic Products Inc. at a facility noncompliant with the agency’s good manufacturing practices regulations.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?